Efficacy of Additional Amiodarone Therapy in Patients with an Implantable Cardioverter-Defibrillator  by Matsumoto, Naomichi et al.
Eﬃcacy of Additional Amiodarone Therapy in Patients
with an Implantable Cardioverter-Deﬁbrillator
Naomichi Matsumoto MD1, Koichiro Kumagai MD2, Masahiro Ogawa MD1,
Kunihiro Matsuo MD1, Tomoo Yasuda MD1, Hideo Takashima MD1,
Chiharu Mitsutake MD1, Soichi Muraoka MD1, Akira Matsunaga MD1,
Shin-ichiro Miura MD1, Keijiro Saku MD1
1Department of Cardiology, Fukuoka University Hospital, School of Medicine
2Heart Rhythm Center, Fukuoka Sanno Hospital
Introduction: We examined whether the additional use of amiodarone (AMD) under
implantable cardioverter-deﬁbrillator (ICD) therapy may have beneﬁcial eﬀects in patients at
risk for lethal ventricular arrhythmias with structural heart diseases.
Methods: Sixty patients (47 males, mean age, 62 13 years) with structural heart disease
who underwent ICD implantation were retrospectively analyzed. There were 2 groups: one
group (AMD group) was treated with AMD (n ¼ 33) and the other group (non-AMD group)
was treated without AMD (n ¼ 27). We compared the incidence and appropriateness of ICD
shock therapy between two groups.
Results: During a mean follow-up of 28 17 months, we identiﬁed a total of 62 episodes in
18 patients (30%) who received ICD shock therapy. ICD shock episodes were signiﬁcantly
less frequent in AMD group than in non-AMD group (15% versus 48%, P < 0:01), while
inappropriate shock episodes were greater in non-AMD group than in AMD group (49%
versus 4%, P ¼ 0:03). In cumulative probability of shock events, the risk of events was
signiﬁcantly lower in AMD group (P ¼ 0:007). Of 4 patients who died in AMD group, we
observed one fatal pulmonary ﬁbrosis.
Conclusions: Additional AMD therapy in patients with an ICD may be eﬀective in reducing
the risk of shock discharge.
(J Arrhythmia 2010; 26: 103–110)
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Introduction
Patients with advanced left ventricular dysfunc-
tion are at risk for life-threatening ventricular
arrhythmia. After the results of the Cardiac Arrhyth-
mia Suppression Trial (CAST), class III drugs,
particularly amiodarone (AMD), have been advo-
cated as the best antiarrhythmic drugs available to
treat such patients who are at high risk of sudden
cardiac death. Several recent trials have demonstrat-
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ed that implantable cardioverter-deﬁbrillator (ICD)
therapy is superior to antiarrhythmic drug treatment
including AMD for the primary or secondary
prevention of sudden cardiac death, and this has
resulted in the frequent use of ICD over the past few
years.1–3) However, it is possible that ICD discharge
for rapid ventricular tachycardia (VT) or ventricular
ﬁbrillation (VF) may decrease the quality of life in
ICD-treated patients and may lead to premature
battery depletion. In addition, the frequency of ICD
shock is often associated with increased psycholog-
ical distress in patients with an ICD and their
families.4,5) Since Class III antiarrhythmic drugs,
such as AMD and sotalol, can help prevent the
occurrence of VT or VF, an antiarrhythmic medi-
cation in ICD-implanted patients may have favorable
eﬀects by reducing both appropriate and inappro-
priate ICD discharges. AMD is particularly useful
in the acute management of sustained ventricular
arrhythmias regardless of hemodynamic stability.
AMD may slow the frequency of VT, making it
amenable to antitachycardia pacing (ATP). Since
most published data suggest that approximately 10–
30% of patients with an ICD experience an electrical
storm in their clinical course,6) and since multiple
high-energy discharges are common during an
electrical storm and are associated with a poor
clinical outcome, combination therapy may help to
suppress a ventricular electrical storm.
Therefore, we tested the hypothesis that the use of
AMD in ICD-treated patients may have beneﬁcial
eﬀects in patients at risk for lethal ventricular
arrhythmias with structural heart diseases.
Methods
We retrospectively evaluated all 65 consecutive
patients with structural heart disease who had an
ICD implanted between April 1998 and May 2005.
Eligible patients had sustained VT, VF, or cardiac
arrest (not within 72 hours of acute myocardial
infarction), unexplained syncope with VT or VF that
was inducible by programmed ventricular stimula-
tion. Patients who received class I, class III drugs
such as sotalol, or combination therapy with drugs in
these classes were excluded (n ¼ 3), and those who
received combination therapy with AMD and class I
agents were also excluded to clarify the physiolog-
ical eﬀects of AMD (n ¼ 2). Overall, 60 patients
were enrolled in the present study (47 males, 13
females; mean age, 62 13 years). All 60 patients
with structural heart disease included ischemic heart
disease (n ¼ 35), hypertrophic cardiomyopathy
(n ¼ 11), dilated cardiomyopathy (n ¼ 6), hyper-
tensive heart disease (n ¼ 5), ventricular septal
defect (n ¼ 1), cardiac sarcoidosis (n ¼ 1), and
arrhythmogenic right ventricular cardiomyopathy
(n ¼ 1). Recruited patients were divided into two
groups: AMD group (n ¼ 33) and non-AMD group
(n ¼ 27). Prior to ICD implantation, AMD was
initiated and usually used at doses of 400mg twice
daily for two weeks as a loading period, and then at
100–200mg once daily as maintenance.
The prescription of AMD was based on the
presence of one of the following two criteria: (1)
clinical or inducible sustained ventricular tachy-
arrhythmias with severe left ventricular ejection
fraction (LVEF) impairment; (2) congestive heart
failure with sustained or non-sustained ventricular
tachyarrhythmias. Those patients who exhibit the
above criteria were basically prescribed AMD, and
were admitted as AMD group. However, AMD was
avoided in patients who failed to exhibit the above
criteria, or suﬀered from basic lung disease or
chronic liver dysfunction, or had exhibited prior
intolerability to AMD and these were assigned to the
non-AMD group. The optimal concomitant medical
therapy with angiotensin receptor blockers (ARB),
angiotensin-converting enzyme inhibitors (ACE-I),
-blockers, or diuretics was encouraged and at-
tempted throughout the study according to the
underlying heart disease in both groups. None of
the antiarrhythmic agents including class I or class
III drugs was used in non-AMD group patients. To
assess the eﬀects of AMD treatment, transthoracic
echocardiography was obtained at regular follow-up
visits. Measurements including left atrial dimension
(LAD), left ventricular end-diastolic dimension
(LVEDd), and LVEF immediately before the admin-
istration of AMD and at a recent follow-up visit after
the administration of AMD were compared.
Programming and interpretation of ICD
The primary eﬃcacy outcome for the study was
the ﬁrst occurrence of any shock delivered by ICD.
The on-board device memory recorded atrial and
ventricular electrograms around the time of each
therapeutic shock event. These recordings were
analyzed with regard to the appropriateness of each
shock event. A shock event was considered an
appropriate discharge when the detection of VT or
VF based on the algorithm led to the delivery of
an ICD shock. A shock event was considered an
inappropriate discharge when atrial tachyarrhyth-
mias or sinus tachycardia enhancing atrio-ventricular
conduction led to ICD shock therapy. To distinguish
between VT and VF, device-stored atrial and
ventricular electrograms (EGMs) were analyzed for
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rate, onset, regularity, stability, change in axis,
morphology, and atrioventricular (AV) dissociation.
Monomorphic VT was deﬁned as a tachycardia with
abrupt onset, AV dissociation, a change in morphol-
ogy on ventricular EGMs compared to baseline,
<30ms beat-to-beat variation, and mean cycle
length >240{500ms. Polymorphic VT was deﬁned
in the same way except that a morphology change
over time with >30ms beat-to-beat variation was
required. VF had the same deﬁnition as polymorphic
VT except that a mean cycle length <240ms was
required. Although devices were basically program-
med according to the cycle length or presence of
VT/VF prior to implant, detection of VT/VF was
programmed in two zones. VF zone was usually set
to >200 beats/min, and VT zone was usually set to
150–200 beats/min with at least 3 trains of ATP
prior to shock.
An electrical storm was deﬁned as the delivery of
multiple shocks due to the occurrence of 3 or more
separate episodes of VT or VF within a 24-hour
period, where each episode was separated by at least
5 minutes. Even if a patient died during the follow-
up period, all patients were included in the analysis
up to the point of the last contact. In the AMD group,
even if a patient discontinued AMD for any reason,
all patients were included in the analysis up to the
point of that discontinuation. In case of requiring
subsequent prescription of AMD due to the occur-
rence of tachyarrhythmias in non-AMD group,
further analysis following prescription of AMD
was excluded.
Statistical analysis
All continuous variables are expressed as the
mean  standard deviation. Statistical analysis was
performed with StatView 5.0J (SAS Institute Inc.,
Cary, USA) software. The statistical signiﬁcance of
diﬀerences between AMD and non-AMD groups
was determined using Student’s t-test. The cumu-
lative risk of ICD shock events was assessed using
the Kaplan-Meier analysis, and diﬀerences among
groups were compared using the log-rank test. For
all analyses, P < 0:05 was considered to be statisti-
cally signiﬁcant.
Results
Clinical characteristics
The clinical characteristics of the patients are
shown in Table 1. There were no signiﬁcant dif-
ferences in baseline characteristics between AMD
and non-AMD groups in terms of age, gender,
syncope, cardio-pulmonary resuscitation rate, distri-
bution of underlying heart disease, inducibility of
VT or VF, clinical atrial ﬁbrillation (AF), and ARB,
ACE-I, -blocker use. The documented ventricular
tachyarrhythmias prior to ICD implant also did not
diﬀer between the two groups. The incidence of
congestive heart failure tended to be higher, and
LVEF was lower in AMD group, but these trends did
not reach statistical signiﬁcance. The proportion of
patients who received a -blocker was relatively
small in both groups (AMD group: 30% versus non-
AMD group: 37%, P ¼ NS).
Echocardiographic parameters
Echocardiographic parameters were compared
between baseline and recent follow-up visit in each
group. There were no signiﬁcant diﬀerences in LAD,
LVEDd, and LVEF between the groups during
follow-up periods. Although there was a trend
toward the enlargement of LVEDd in the AMD
group (59 13mm to 62 15mm, P ¼ 0:07), it did
not reach statistical signiﬁcance.
Shock events with an ICD
Table 2 shows the observed shock event rates for
28 17 months of follow-up in both treatment
groups. We identiﬁed a total of 62 episodes in 18
patients (30%) who received ICD shock therapy. The
number of patients who experienced ICD shock
events in the AMD group was signiﬁcantly lower
than that in the non-AMD group (AMD group: 15%
versus non-AMD group: 48%, P < 0:01). The total
number of shock events in the AMD and non-AMD
group was 27 episodes (5 patients) and 35 episodes
(13 patients), respectively. Although there was no
signiﬁcant diﬀerence in the total number of shock
events between the two groups, the incidence of
inappropriate shock events due to rapid atrial
tachyarrhythmias and sinus tachycardia was signiﬁ-
cantly lower in the AMD group than in the non-
AMD group (AMD group: 4% versus non-AMD
group: 49%, P ¼ 0:03). There was only one inap-
propriate episode due to AF in the AMD group,
while there were 17 inappropriate episodes including
rapid AF (14 episodes in 5 patients) and sinus
tachycardia (3 episodes in 2 patients) in the non-
AMD group. Of the 5 patients who received
inappropriate episodes due to rapid AF in the non-
AMD group, 4 had a paroxysmal and 1 had chronic
AF in baseline state. Regarding the appropriate
shock events, there was a trend towards a higher risk
in the AMD group than in the non-AMD group.
(AMD group: 96% versus non-AMD group: 51%,
P ¼ 0:06). During the entire follow-up period, two
patients experienced electrical storms. An electrical
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storm due to polymorphic VT was observed in 1
patient with ischemic heart disease in the AMD
group (total 19 shock events within consecutive 3
days), and the remaining 1 patient with dilated
cardiomyopathy in the non-AMD group (3 shock
events following ATP within 30 minutes within a 24-
hour period).
Figure 1 shows the cumulative probability of shock
events after ICD implant for the two treatment
groups. The risk of shock events was signiﬁcantly
lower in AMD group than in non-AMD group
(P ¼ 0:007).
Adverse effects
Table 3 shows the adverse eﬀects in the two
treatment groups. In-hospital death occurred in 4
patients in the AMD group for a mortality rate of
12%. Of these 4 patients death was caused by
pulmonary ﬁbrosis in one, and by worsening of
congestive heart failure in the remaining 3. There
were no signiﬁcant diﬀerences in death rates
between the two groups (12% versus 11%). Al-
though the incidence of admission due to congestive
heart failure was lower in the AMD group, this
diﬀerence was not statistically signiﬁcant (3% versus
15%, P ¼ 0:09). In the AMD group, there were
higher rates of adverse thyroid and pulmonary
eﬀects, and there were no cases of torsade de
pointes.
Discussion
In patients who received ICD therapy for secon-
dary prevention of lethal ventricular arrhythmias, the
present study demonstrated that the frequency of
ICD shock therapy in the AMD group was signiﬁ-
cantly lower than that in the non-AMD group.
Inappropriate shock therapy precipitated by supra-
ventricular tachyarrhythmias (primarily rapid AF)
occurred more frequently in the non-AMD group
than in the AMD group. Although therapy by ICD
implantation is eﬀective for terminating life-threat-
ening ventricular arrhythmias and improving surviv-
al rates compared to conventional antiarrhythmic
drug therapy,7,8) an ICD device is basically designed
to treat VT or VF. However, ICD shock therapy
Table 1 Baseline characteristics
Characteristics All(n ¼ 60)
AMD group
(n ¼ 33)
non-AMD group
(n ¼ 27) p
Age 62 13 64 13 58 13 0.09
Gender (male, %) 47 (78) 25 (76) 22 (81) 0.59
Syncope (%) 20 (33) 9 (27) 11 (41) 0.24
CPR (%) 20 (33) 10 (30) 10 (37) 0.84
Underlying heart disease (%)
Ischemic heart disease 35 (58) 19 (58) 16 (59) 0.90
Hypertrophic cardiomyopathy 11 (18) 6 (18) 5 (19) 0.82
Dilated cardiomyopathy 6 (10) 3 (9) 3 (11) 0.72
Hypertensive heart disease 5 (8) 3 (9) 2 (7) 0.81
Others 3 (5) 2 (6) 1 (4) —
Documented ventricular arrhythmia (%)
VF 17 (28) 8 (24) 9 (33) 0.78
Monomorphic VT 20 (33) 14 (42) 6 (22) 0.09
Polymorphic VT 18 (30) 10 (30) 8 (30) 0.82
Paroxysmal AF 12 (20) 5 (15) 7 (26) 0.12
Chronic or persistent AF 7 (12) 4 (12) 3 (11) 0.84
Heart failure (%) 20 (33) 14 (42) 6 (22) 0.09
Inducible VT or VF (%) 37/39 (95) 21/21 (100) 16/18 (89) 0.12
LVEF (%) 49 18 45 16 53 19 0.09
Baseline medication
ACE inhibitor or ARB (%) 46 (77) 26 (79) 20 (74) 0.60
-blocker (%) 20 (33) 10 (30) 10 (37) 0.58
All continuous variables presented as mean  standard deviation.
AMD: amiodarone, CPR: cardiopulmonary resuscitation, AF: atrial ﬁbrillation, VT: ventricular tachycardia, VF: ventricular
ﬁbrillation, LVEF: left ventricular ejection fraction, ACE: angiotensin converting enzyme, ARB: angiotensin receptor blocker
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adversely aﬀects the quality of life. The delivery of
inappropriate or even appropriate shocks may pro-
voke serious psychological reactions, and unneces-
sary shock therapy may lead to premature battery
depletion. A recent study showed that in patients
with heart failure who received an ICD for primary
prevention, the occurrence of both appropriate and
inappropriate ICD shock therapy were associated
with markedly increased risk of death, particularly
death from progressive heart failure.9) The cause of
increased risk may be postulated that the negative
inotropic consequences of the shock itself could
increase the risk of death, especially when the
patient receives multiple shocks due to oversensing
or in response to ongoing supraventricular tachycar-
dia.10–13) Thus, eﬀective strategies to reduce ICD
shocks are desirable. Antiarrhythmic medication is
frequently administered in patients with an ICD.
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Table 2 ICD shock therapy in AMD and non-AMD groups
AMD group
(n ¼ 33)
non-AMD group
(n ¼ 27) p Value
No. of patients with
ICD discharge (%) 5/33 (15%) 13/27 (48%) 0.01>
Total episodes of
ICD discharge 27 35 0.43
Episode No. of
appropriate discharge (%) 26/27 (96%) 18/35 (51%) 0.06
Episode No. of
inappropriate discharge (%) 1/27 (4%) 17/35 (49%) 0.03
Follow-up periods
(months, mean SD) 27.9  16.8 29.1  18.3 0.79
AMD: amiodarone, ICD: implantable cardioverter-deﬁbrillator
26 appropriate discharge in AMD group include 19 episodes due to the occurrence of electrical storm in one patient
with severe ischemic heart disease. 18 appropriate discharge in non-AMD group include 3 episodes due to the
occurrence of electrical storm in one patient with dilated cardiomyopathy.
Figure 1 Cumulative probability for the 2 treatment
groups
Kaplan-Meier curve shows the cumulative probability in the
two treatment groups. The risk of shock events in the AMD
group (solid line) was signiﬁcantly lower than that in the
non-AMD group (small dotted line).
Table 3 Adverse events of the 2 treatment groups
Adverse events AMD group(n ¼ 33)
non-AMD group
(n ¼ 27) p Value
Death 4 (12%) 3 (11%) 0.90
Admission due to CHF 1 (3%) 4 (15%) 0.09
Pulmonary disease 2 (6%) 0 0.19
Hypothyroidism 2 (6%) 0 0.19
Corneal microdeposits 3 (9%) 0 0.11
AMD: amiodarone, CHF: congestive heart failure
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Most importantly, drug therapy can reduce or
eliminate ICD shocks by suppressing ventricular
arrhythmias or by slowing ventricular tachycardia so
that it can be terminated with programmed ATP.
In addition to the suppression of such appropriate
shocks, antiarrhythmic therapy may suppress inap-
propriate shocks precipitated by supraventricular
tachyarrhythmias such as AF. Deﬁbrillator shocks
also might contribute to rehospitalization14) and
myocardial injury.15) Since ICD shocks have been
associated with reduced physical capacity and
impaired quality of life, the suppression of such
events may have important clinical beneﬁts. The
results of the Optimal Pharmacological Therapy in
Cardioverter Deﬁbrillator Patients (OPTIC) trial16)
showed that a combination of AMD plus -blocker
therapy more often prevented appropriate or inap-
propriate shocks than -blocker alone. Previous
studies have suggested that AMD prevents the
recurrence of VT, VF and unexpected death, and
reduces the total mortality in patients with ventric-
ular tachyarrhythmias.17–20) These studies indicate
AMD may be eﬀective as an adjunct to ICD therapy
to reduce the number of shocks.
In an analysis of data from the OPTIC trial, AMD
plays an important role to prevent both type of
shocks. The present study demonstrates that there
were a smaller number of patients who received ICD
discharge in the AMD group than in the non-AMD
group during follow-up, and the incidence of ICD
discharge due to inappropriate tachycardia detection
was eﬀectively reduced by AMD therapy. These
results support the OPTIC trial data, whereas AMD
was insuﬃcient to suppress appropriate discharges
contrary to our expectations. It is important to
emphasize that the majority of appropriate discharg-
es reﬂect the excessive number of discharges due
to an electrical storm (19 out of a total of 26
appropriate episodes) in one patient. Furthermore,
the possibility may be considered that the limited
number of patients receiving -blockers increased
the risk of appropriate events. Additionally, the
incidence of paroxysmal AF in baseline state was not
balanced between the two groups (15% in AMD
group versus 26% in non-AMD group, P ¼ 0:12). It
should be noted that this relatively higher incidence
of paroxysmal AF in the non-AMD group might be a
reason for the greater frequency of inappropriate
ICD in the non-AMD group than in the AMD group.
Hemodynamics
In the present study, there were no signiﬁcant
changes in the echocardiographic parameters during
the follow-up period in the AMD group. This result
might be mainly due to the small number of patients
who received a -blocker (30% in AMD group).
-adrenergic blocking agents have antiadrenergic
eﬀects, which contribute to the cardiac ionic channel
properties of AMD. Since -blocker therapy is
widely used in patients with an ICD for heart failure
or post-myocardial infarction, it is practical to test
the additional eﬀects of AMD. Subgroup analysis of
AMD in post-myocardial infarction trials has sug-
gested that AMD is particularly eﬀective when used
with a -blocker.21) If a -blocker was more
frequently used in the AMD group in the present
study, then hemodynamic measurements in the
AMD group might be expected to improve during
follow-up. On the other hand, it has been reported
that AMD monotherapy resulted in a substantial
increase in left ventricular systolic function in
patients with congestive heart failure (LVEF <
40%). A signiﬁcant increase in LVEF (8.8% increase
after 24 months) was noted in an AMD group
compared with a placebo-controlled group.22) Since
AMD itself inhibits adrenergic excitation by a non-
competitive mechanism, this may explain its positive
eﬀect on LVEF. To evaluate the association between
AMD and cardiac hemodynamics, a further random-
ized prospective clinical study will be required.
Adverse effects
AMD has several potential adverse eﬀects includ-
ing pulmonary, thyroid, skin, and corneal disorders.
Adverse pulmonary and thyroid eﬀects were com-
mon among patients who received AMD over just 1
year, and it can be expected that toxicity would be
even more common over a longer follow-up. In
the OPTIC study, these adverse eﬀects resulted in
discontinuation of the drug in 18% of the patients
receiving AMD.16) In the present study, AMD
treatment was associated with a higher frequency
of pulmonary and thyroid adverse events. Fatal
pulmonary ﬁbrosis during AMD therapy was ob-
served in one patient. Although it is diﬃcult to
predict individual patient responses because of the
unique pharmacokinetics and pharmacodynamics of
AMD, this result indicates that close follow-up is
mandatory to detect adverse eﬀects.
Study limitations
There are several limitations of our study. The
present ﬁndings are limited by the retrospective
nature of the design and its restriction to a single
center patient population. Other limitations include
the relatively small number of patients in the later
years of follow-up, and lack of information on other
variables that may inﬂuence the risk of lethal
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arrhythmias, such as interim cardiovascular events
and medication changes. We could not determine
precisely whether there was an additional prescrip-
tion of -blocker or other antiarrhythmic agents such
as class I or class IV agents throughout the entire
follow-up. Especially, the limited number of patients
receiving -blockers in baseline state may be
considerably inﬂuenced the results in the present
study because of some other subsequent initiation of
-blockers. Additionally, the incidence of inappro-
priate shock events was signiﬁcantly lower in the
AMD group than in the non-AMD group, while there
was a trend towards a higher risk of the appropriate
shock events in the AMD group than in the non-
AMD group. This higher incidence of appropriate
events in the AMD group was probably attributable
to the electrical storm in 1 patient. Of note, although
ATP is usually used in patients with sustained
monomorphiv VT, we did not include ATP therapy
in the present analysis. The incidence of documented
monomorphic VT prior to ICD implant tends to be
higher in the AMD group (Table 1), which may have
signiﬁcantly modiﬁed the incidence of shock therapy
in the AMD group due to eﬀective ATP to mono-
morphic VT.
Although the present study suggests that AMD is
likely to improve quality of life due to the reduction
of ICD discharge in patients with an ICD, quanti-
tative analysis to assess each patient’s health status
before and after ICD shock was not performed on
this study. Finally, the prognostic eﬀect was unde-
termined because of the short follow-up. Thus, a
further prospective clinical study with long-term
follow-up is required to conﬁrm this ﬁnding.
Conclusion
Despite the proven eﬃcacy of ICD therapy for
treating lethal ventricular arrhythmias, adverse ef-
fects due to ICD shock therapy still remains a
signiﬁcant clinical issue. Thus, an eﬀective strategy
to avoid frequent shocks may be crucial for the
safety of patients with an ICD. The present study
suggests that the use of AMD in patients with ICD
therapy was associated with a reduced incidence of
ICD discharge without changes in left ventricular
function. Especially, AMD may be useful and
eﬀective in management of inappropriate discharge
due to rapid AF. However, it should be noted that
therapeutic decisions have to consider the risks of
fatal AMD-related adverse eﬀects such as pulmo-
nary ﬁbrosis with close follow-up. Finally, the risks
and beneﬁts of AMD should be compared with
alternative strategies in each individual patient.
When these items are considered, AMD may help
to improve quality of life for patients with an ICD.
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